The prevalence of the hepatitis C virus among the conditionally healthy population of the Russian Federation

Aim. To determine the prevalence of hepatitis C virus (HCV) in different age groups of the conditionally healthy population of Russia.

Materials and methods. Total 4764 serum samples from a conditionally healthy population of five regions of Russia (Moscow, Rostov, Sverdlovsk regions, Tyva Republic, and Sakha Republic (Yakutia) were tested. The study included persons of 10 age groups: < 1 year, 1–4 years, 5–9 years, 10–14 years, 15–19 years, 20–29 years, 30–39 years, 40–49 years, 50–59 years old, ≥ 60 years. Anti-HCV was determined in ELISA with commercial test systems. Anti-HCV positive samples were tested for HCV RNA by RT-PCR. The genotype of HCV was determined based on the analysis of the nucleotide sequences of the core and NS5B regions of the viral genome.

Results. The overall prevalence of anti-HCV in 5 regions of Russia was 2,6% (126/4764), and the proportion of people with HCV RNA was 1,1% (50/4764). The highest anti-HCV positivity rate was observed in Tyva and Yakutia (3,3% in both regions), in other regions its prevalence varied from 1,7% (Moscow region) to 3,0% (Sverdlovsk region). The highest frequency of HCV RNA detection was observerd in Tyva Republic and Rostov region (1.3% in both regions). No positive for HCV RNA cases was detected among persons aged 0–19 years in any region, except for Tyva Republic (1,0% (1/98) in age group 15–19 years). Peak positivity rates of HCV RNA were detected in the age groups 20–29 years and 30–39 years in the Rostov Region (3,9% and 3,0%, respectively); in Yakutia – in the group of 30–39 years (3,7%), in Tyva – in the group of 40–49 years (3,6%), in the Moscow region – in the groups of 20–29 and 30–39 years (2,9% and 2,5%, respectively).

Conclusion. The results obtained indicate a high degree of HCV infection in virtually all age groups in the interval from 20 years to ≥60 years. Specific age cohorts that might benefit from inclusion in regional HCV screening programs were identified in each region. 

1. Lobzin Ju.V.,Zhdanov K.V., Volzhanin V.M., Gusev D.A. i dr. Virusnye gepatity: klinika, diagnostika, lechenie [viral hepatitis: clinic, diagnostics, therapy]. Sankt-Peterburg: Foliant, 2006, 184 p.

2. Zhdanov K.V., Lobzin Ju.V., Gusev D.A. Kozlov K.V. Virusnye gepatity [Viral hepatitis]. Sankt-Peterburg: Foliant, 2011. 304 p.

3. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010 Lancet 2012;380:2095-2128.

4. Global policy report on the prevention and control of viral hepatitis in WHO Member States. Geneva: World Health Organization; 2013. (http://apps.who.int/iris/bitstream/10665/85397/1/9789241564632_eng.pdf, accessed 21 January 2014)

5. Durham DP, Skrip LA, Bruce RD, Vilarinho S, Elbasha EH, Galvani AP, Townsend JP. The Impact of Enhanced Screening and Treatment on Hepatitis C in the United States. Clin Infect Dis. 2016 Feb 1;62(3):298-304.

6. Cipriano, L.E., Zaric, G.S., Holodniy, M., Bendavid, E., Owens, D.K., & Brandeau, M.L. Cost Effectiveness of Screening Strategies for Early Identification of HIV and HCV Infection in Injection Drug Users. PLОS ONE, 2012.

7. Global Burden of Disease Hepatitis C Working Group. Global burden of disease (GBD) for hepatitis C. J Clin Pharmacol 2004; 44:20-29.

8. Shepard CW, Finelli L, Alter M J. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005;5:558-567.

9. Mukomolov S.L., Levakova I.A., Sulyagina L.G., Sinayskaya E.V., Bolsun D.D., Ivanova N.V. Sovremennaja epidemiologiya gepatita C v Rossii [Current epidemiology of hepatitis C in Russia]. Epidemiologiya i infekcionnye bolezni, 2012, No 6, pp. 21-25.

10. Fan, W.M., Zhu, W. F., Zwang, S. Y., Wang, Q. X., Yin, L. M., Wan, H., et al. Nine-year follow-up of hepatitis C virus infection in a rural area of Hebei province, China. Chung-Hua i Hsueh Tsa Chih Chinese Medical Journal 2004, 84, 392-6.

11. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006;144:705-714.

12. Smith BD, Morgan RL, Beckett GA, Falck-Ytter Y, Holtzman D, Teo CG, et al.; Centers for Disease Control and Prevention (CDC). Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. MMWR Recomm Rep 2012;61(No. RR-4):1-32. Erratum in: MMWR Recomm Rep. 2012;61:886

13. McGarry LJ, Pawar VS, Panchmatia HR, Rubin JL, Davis GL, Younossi ZM, Capretta JC, O’Grady MJ, Weinstein MC. Economic model of a birth cohort screening program for hepatitis C virus. Hepatology. 2012 May;55(5):1344-55

14. Virusnye gepatity v Rossijskoj Federacii. Analiticheskij obzor. 10 vypusk [Viral hepatitis in Russian Federation. Analytical review. 10th edition]. Ed.: V.I. Pokrovskiy, A.A. Totolyan. – SPb.:FBUN NIIJeM imeni Pastera, 2016, 152 p.

15. Wasley A, Alter MJ. Epidemiology of hepatitis C: geographic differences and temporal trends. Semin Liver Dis 2000;20:1-16

16. Akimkin V.G. Vnutribol’nichnoe inficirovanie virusami gepatitov B i C: epidemiologiya i napravleniya profilaktiki [Intrahospital infection of hepatitis B and C^ epidemiology and prophylaxis]. Epidemiologiya i infekcionnye bolezni, 2004, No6, pp. 13-17.

17. Ershova O.N. Sovremennye proyavleniya epidemicheskogo processa gepatita C, aktivnost’ estestvennyh putej peredachi i sovershenstvovanie profilaktiki etoy infekcii [Current manifestations of the epidemic process of hepatitis C, the activity of natural transmission routes and the improvement of the prevention of this infection]. avtoref. diss. dokt. med. nauk, 2006,38 p.

18. Pimenov N.N., Chulanov V.P., Komarova S.V. Gepatit C v Rossii: epidemiologicheskaya harakteristika i puti sovershenstvovaniya diagnostiki i nadzora [Hepatitis C in Russia: epidemiological characteristics and ways to improve diagnostics and surveillance]. Epidemiologiya i infekcionnye bolezni, 2012, No 3, pp. 4–10.

19. Kurbanov F, Tanaka Y, Chub E. et al Molecular epidemiology and interferon susceptibility of the natural recombinant hepatitis c virus strain RF1_2k/1b. J.Infect. Dis. 2008, 15, 198(10), 1448-1456.

20. Isaeva O.V., Kichatova V.S., Karlsen A.A., Solonin S.A., Dmitriev P.N., Kyuregyan K.K., Mikhailov M.I. Mnogoletnjaja dinamika rasprostranenija genotipov virusa gepatita S v Moskovskom regione [Long-term dynamics of the spread of hepatitis C virus genotypes in the Moscow region]. ZhMJeI, 2016, No 4, pp. 35-42.

21. Narkewcz, M.R., Carbera R., et al. The “C” of viral hepatitis in children//Semin Liver Dis. 2007. Aug, Vol.27.-P.295-311.